Department of Oncology, Shouguang People's Hospital, Shouguang, Shandong 262700, P.R. China.
Department of Thoracic Surgery, Weifang Hospital of Traditional Chinese Medicine, Weifang, Shandong 261041, P.R. China.
Mol Med Rep. 2019 Mar;19(3):1747-1752. doi: 10.3892/mmr.2019.9813. Epub 2019 Jan 3.
An increasing number of studies have demonstrated that microRNAs (miRNAs/miRs) are involved in cancer progression. In 2010, an estimated 1,500,000 patients suffered mortality from lung cancer (LC) worldwide, and ~80% of LC patients were diagnosed with non‑small‑cell lung cancer (NSCLC). miR‑584‑5p was reported to be a potential biomarker in the diagnosis of LC; in addition, miR‑584 was recently observed to suppress the progression of thyroid carcinoma, glioma and gastric cancer. However, the specific function of miR‑584‑5p in NSCLC remains unclear. In the present study, miR‑584‑5p was decreased in the tumor tissues of NSCLC patients. Furthermore, miR‑584‑5p markedly inhibited the migration and invasion of NSCLC cells. The direct regulatory association between miR‑584‑5p and matrix metalloproteinase (MMP)‑14 was verified by a luciferase reporter gene assay. Furthermore, the results indicated that miR‑584‑5p inhibited the expression of MMP‑14 at the protein and mRNA levels. miR‑584‑5p also inhibited the expression of MMP‑4 and Slug, which are involved in tumor invasion and metastasis. Taken together, these results indicated that the miR‑584‑5p/MMP‑14 axis may serve as an anticancer target in the treatment of NSCLC patients.
越来越多的研究表明 microRNAs(miRNAs/miRs)参与了癌症的进展。2010 年,全球估计有 150 万肺癌(LC)患者死亡,约 80%的 LC 患者被诊断为非小细胞肺癌(NSCLC)。miR-584-5p 被报道为 LC 诊断的潜在生物标志物;此外,miR-584 最近被观察到可抑制甲状腺癌、神经胶质瘤和胃癌的进展。然而,miR-584-5p 在 NSCLC 中的具体功能尚不清楚。在本研究中,miR-584-5p 在 NSCLC 患者的肿瘤组织中减少。此外,miR-584-5p 显著抑制了 NSCLC 细胞的迁移和侵袭。通过荧光素酶报告基因检测证实了 miR-584-5p 与基质金属蛋白酶(MMP)-14 之间的直接调控关系。此外,结果表明 miR-584-5p 抑制了 MMP-14 的蛋白和 mRNA 水平的表达。miR-584-5p 还抑制了 MMP-4 和 Slug 的表达,它们参与肿瘤的侵袭和转移。综上所述,这些结果表明 miR-584-5p/MMP-14 轴可能成为治疗 NSCLC 患者的抗癌靶点。